{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:09:50Z","timestamp":1780308590496,"version":"3.54.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10384-025-01318-9","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:48:28Z","timestamp":1777085308000},"page":"527-537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and risk factors related to ocular adverse effects caused by S-1 chemotherapy"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6416-0474","authenticated-orcid":false,"given":"Tomoyuki","family":"Kamao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The TS-1 study working group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohtomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-ichiro","family":"Chikama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hosotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihito","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs"},{"key":"1318_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"1318_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/annonc\/mdm439","volume":"19","author":"YJ Kim","year":"2008","unstructured":"Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol. 2008;19:99\u2013103.","journal-title":"Ann Oncol"},{"key":"1318_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"1318_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853\u201360.","journal-title":"Lancet Oncol"},{"key":"1318_CR6","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1200\/JCO.2010.31.0326","volume":"28","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010;28:5240\u20136.","journal-title":"J Clin Oncol"},{"key":"1318_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40265-013-0062-y","volume":"73","author":"M Sanford","year":"2013","unstructured":"Sanford M. S-1 (Teysuno\u00ae): a review of its use in advanced gastric cancer in non-Asian populations. Drugs. 2013;73:845\u201355.","journal-title":"Drugs"},{"key":"1318_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10384-015-0421-1","volume":"60","author":"R Yamada","year":"2016","unstructured":"Yamada R, Sotozono C, Nakamura T, Nishida A, Nakanishi S, Hirabatake M, et al. Predictive factors for ocular complications caused by anticancer drug S-1. Jpn J Ophthalmol. 2016;60:63\u201371.","journal-title":"Jpn J Ophthalmol"},{"key":"1318_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ajo.2005.01.052","volume":"140","author":"B Esmaeli","year":"2005","unstructured":"Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140:325\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1318_CR10","first-page":"919","volume":"110","author":"S Ito","year":"2006","unstructured":"Ito S, Tanaka A. Three cases of corneal disorders associated with an oral anticancer drug S-1. Nippon Ganka Gakkai Zasshi. 2006;110:919\u201323 ((in Japanese)).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1318_CR11","first-page":"2896","volume":"15","author":"T Chikama","year":"2009","unstructured":"Chikama T, Takahashi N, Wakuta M, Nishida T. Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1. Mol Vis. 2009;15:2896\u2013904.","journal-title":"Mol Vis"},{"key":"1318_CR12","first-page":"23","volume":"121","author":"Y Inoue","year":"2017","unstructured":"Inoue Y, Shiraishi A, Sugioka K, Yokoi N, Chikama TI, Sakimoto T, et al. The Japan Cornea Society survey of the current status of corneal and conjunctival disorders due to systemic antitumor drugs. Nippon Ganka Gakkai Zasshi. 2017;121:23\u201333 ((in Japanese)).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1318_CR13","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/annonc\/mds106","volume":"23","author":"N Kim","year":"2012","unstructured":"Kim N, Park C, Park DJ, Kim HH, Kim S, Kim YJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012;23:2065\u201371.","journal-title":"Ann Oncol"},{"key":"1318_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1874364101307010085","volume":"7","author":"K Sato","year":"2013","unstructured":"Sato K, Nishimura S. Adverse effects of the oral anticancer drug S-1: lacrimal passage impairment and specific features of corneal epitheliopathy. Open Ophthalmol J. 2013;7:85\u20136.","journal-title":"Open Ophthalmol J"},{"key":"1318_CR15","doi-asserted-by":"publisher","first-page":"iv531","DOI":"10.1093\/annonc\/mdu356.43","volume":"25","author":"T Onikubo","year":"2014","unstructured":"Onikubo T, Nakamura M, Nakamura K, Uchibori K, Tauchi K. 1522P\u2014Prospective study of ocular adverse events induced by S-1. Ann Oncol. 2014;25:iv531.","journal-title":"Ann Oncol"},{"key":"1318_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4143\/crt.2016.569","volume":"50","author":"N Kim","year":"2018","unstructured":"Kim N, Kim JW, Baek JH, Kim JS, Choung HK, Kim TY, et al. S-1-induced lacrimal drainage obstruction and its association with ingredients\/metabolites of S-1 in tears and plasma: a prospective multi-institutional study. Cancer Res Treat. 2018;50:30\u20139.","journal-title":"Cancer Res Treat"},{"key":"1318_CR17","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s10120-015-0540-x","volume":"19","author":"H Tabuse","year":"2016","unstructured":"Tabuse H, Kashiwagi H, Hamauchi S, Tsushima T, Todaka A, Yokota T, et al. Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy. Gastric Cancer. 2016;19:894\u2013901.","journal-title":"Gastric Cancer"},{"key":"1318_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10384-025-01180-9","volume":"69","author":"M Yamada","year":"2025","unstructured":"Yamada M, Kamao T, Shiraishi A, Sakai J, Ohashi Y. Ocular complication induced by anticancer drug S-1: association with drug concentrations in tears. Jpn J Ophthalmol. 2025;69:447\u201352.","journal-title":"Jpn J Ophthalmol"},{"key":"1318_CR19","first-page":"221","volume":"21","author":"MA Lemp","year":"1995","unstructured":"Lemp MA. Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221\u201332.","journal-title":"CLAO J"},{"key":"1318_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1001\/archopht.1969.00990020012003","volume":"82","author":"OP van Bijsterveld","year":"1969","unstructured":"van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol. 1969;82:10\u20134.","journal-title":"Arch Ophthalmol"},{"key":"1318_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0161-6420(00)00599-6","volume":"108","author":"M Dogru","year":"2001","unstructured":"Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology. 2001;108:586\u201392.","journal-title":"Ophthalmology"},{"key":"1318_CR22","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1111\/aos.12260","volume":"92","author":"X Zheng","year":"2014","unstructured":"Zheng X, Kamao T, Yamaguchi M, Sakane Y, Goto T, Inoue Y, et al. New method for evaluation of early phase tear clearance by anterior segment optical coherence tomography. Acta Ophthalmol. 2014;92:e105\u201311.","journal-title":"Acta Ophthalmol"},{"key":"1318_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2147\/OPTH.S409662","volume":"17","author":"J Nakamura","year":"2023","unstructured":"Nakamura J, Kamao T, Mitani A, Mizuki N, Shiraishi A. Accuracy of the lacrimal syringing test in relation to dacryocystography and dacryoendoscopy. Clin Ophthalmol. 2023;17:1277\u201385.","journal-title":"Clin Ophthalmol"},{"key":"1318_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA statement on p-values: context, process, and purpose. Am Stat. 2016;70:129\u201333.","journal-title":"Am Stat"},{"key":"1318_CR25","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1080\/02713683.2020.1760305","volume":"45","author":"T Kamao","year":"2020","unstructured":"Kamao T, Takahashi N, Zheng X, Shiraishi A. Changes of visual symptoms and functions in patients with and without dry eye after lacrimal passage obstruction treatment. Curr Eye Res. 2020;45:1590\u20137.","journal-title":"Curr Eye Res"},{"key":"1318_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.06.022","volume":"181","author":"S Koh","year":"2017","unstructured":"Koh S, Inoue Y, Ochi S, Takai Y, Maeda N, Nishida K. Quality of vision in eyes with epiphora undergoing lacrimal passage intubation. Am J Ophthalmol. 2017;181:71\u20138.","journal-title":"Am J Ophthalmol"},{"key":"1318_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ajo.2011.01.022","volume":"152","author":"Y Kabata","year":"2011","unstructured":"Kabata Y, Goto S, Takahashi G, Tsuneoka H. Vision-related quality of life in patients undergoing silicone tube intubation for lacrimal passage obstructions. Am J Ophthalmol. 2011;152:147-50.e2.","journal-title":"Am J Ophthalmol"},{"key":"1318_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12886-020-01678-5","volume":"21","author":"T Kamao","year":"2021","unstructured":"Kamao T, Zheng X, Shiraishi A. Outcomes of bicanalicular nasal stent inserted by sheath-guided dacryoendoscope in patients with lacrimal passage obstruction: a retrospective observational study. BMC Ophthalmol. 2021;21:103.","journal-title":"BMC Ophthalmol"},{"key":"1318_CR29","first-page":"271","volume":"66","author":"J Sakai","year":"2012","unstructured":"Sakai J, Inoue Y, Kashiwagi H, Sasaki T. Multi-institutional survey on the lacrimal side effects of TS-1. Rinsho Ganka. 2012;66:271\u20134 ((in Japanese)).","journal-title":"Rinsho Ganka"},{"key":"1318_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1081\/CUS-120015900","volume":"21","author":"H Anne","year":"2002","unstructured":"Anne H, Hanna T, Lotta S, Hannu U. Evaluation of adverse ocular effects of 5-fluorouracil by using human corneal epithelial cell cultures. J Toxicol Cutan Ocul Toxicol. 2002;21:283\u201392.","journal-title":"J Toxicol Cutan Ocul Toxicol"},{"key":"1318_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/eye.1990.83","volume":"4","author":"GR Snibson","year":"1990","unstructured":"Snibson GR, Greaves JL, Soper ND, Prydal JI, Wilson CG, Bron AJ. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye. 1990;4:594\u2013602.","journal-title":"Eye"},{"key":"1318_CR32","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.8.6.2","volume":"8","author":"P Argona","year":"2019","unstructured":"Argona P, Simmons PA, Wang H, Wang T. Physicochemical properties of hyaluronic acid-based lubricant eye drops. Transl Vis Sci Technol. 2019;8:2.","journal-title":"Transl Vis Sci Technol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01318-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01318-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01318-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:55:09Z","timestamp":1780307709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01318-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01318-9","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Kamao, None; M. Yamada, None; A. Shiraishi, None; J. Sakai, None; Y. Ohashi, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}